Which are the causes of Familial Partial Lipodystrophy?

Familial Partial Lipodystrophy is primarily caused by genetic mutations that impair the body's ability to store fat in subcutaneous tissue, leading to an abnormal distribution of body fat. These mutations disrupt the normal function of adipocytes (fat cells) or their development, forcing fat to be stored in ectopic sites like the liver, muscles, or visceral organs.

What genetic factors cause Familial Partial Lipodystrophy?

The etiology of Familial Partial Lipodystrophy is rooted in mutations within specific genes that regulate fat cell development and maintenance. The most common form, Dunnigan-type (FPLD2), is caused by mutations in the LMNA gene, which provides instructions for making lamin A and lamin C proteins. Other subtypes are linked to mutations in genes such as PPARG, PLIN1, CIDEC, and ADRP. These genetic variations prevent the body from effectively maintaining fat stores in the limbs and face, often leading to a lean appearance in those areas while fat accumulates in the trunk or neck.

Is Familial Partial Lipodystrophy hereditary?

Yes, Familial Partial Lipodystrophy is a genetic condition typically inherited in an autosomal dominant pattern. This means an individual only needs one copy of the mutated gene from one parent to manifest the condition. Because Familial Partial Lipodystrophy involves a genetic blueprint, it is present from birth, though physical signs often become more apparent during puberty or early adulthood when hormonal changes influence fat distribution.

How do researchers distinguish between causes and triggers?

It is important to distinguish the genetic cause from clinical triggers. While the Familial Partial Lipodystrophy mutation is the fundamental cause, the severity of metabolic complications—such as insulin resistance, diabetes, and hypertriglyceridemia—can be influenced by environmental factors. Current research is focused on the following areas:

• Genotype-phenotype correlations: Understanding why the same mutation results in different severity levels among individuals.


• Adipose tissue signaling: Researching how defective fat cells communicate with other organs, causing systemic metabolic dysfunction.


• Molecular therapies: Investigating potential treatments that target the specific protein pathways affected by LMNA or PPARG mutations.

Next steps

• Consult with a clinical geneticist to discuss genetic testing and family screening.


• Work with an endocrinologist to manage the metabolic complications associated with Familial Partial Lipodystrophy.


• Connect with the 27 members of the Familial Partial Lipodystrophy community at DiseaseMaps.org to share experiences.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Familial Partial Lipodystrophy


• Orphanet: Familial Partial Lipodystrophy


• OMIM (Online Mendelian Inheritance in Man): Lipodystrophy, Familial Partial


• The Endocrine Society: Clinical Practice Guidelines on Lipodystrophy